DDInter1595 DDInter1676
Rilpivirine is non-nucleoside reverse transcriptase inhibitor (NNRTI) which is used for the treatment of HIV-1 infections in treatment-naive patients. It is a diarylpyrimidine derivative. The internal conformational flexibility of rilpivirine and the plasticity of it interacting binding site gives it a very high potency and reduces the chance of resistance compared to other NNRTI's. Rilpivirine was developed by Tilbotec, Inc. and FDA approved on May 20, 2011. On November 21, 2017, Rilpivirine, in combination with [dolutegravir], was approved as part of the first complete treatment regimen with only two drugs for the treatment of adults with HIV-1 named Juluca. Rilpivirine in combination with [cabotegravir] was granted FDA approval on 21 January 2021. While previously
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Rilpivirine {u} (Compound) resembles {v} (Compound) Etravirine
Rilpivirine {u} (Compound) binds {v} (Gene) CYP3A4
Rilpivirine {u} (Compound) is included by {v} (Pharmacologic Class) Non-Nucleoside Reverse Transcriptase Inhibitors
Rilpivirine {u} (Compound) causes {v} (Side Effect) Blood creatinine increased
Rilpivirine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Rilpivirine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Zafirlukast
Rilpivirine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lorlatinib
Rilpivirine {u} may lead to a major life threatening interaction when taken with {v} Lumacaftor
Rilpivirine {u} may lead to a major life threatening interaction when taken with {v} Ranitidine
Rilpivirine {u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pazopanib
Rilpivirine (Compound) resembles Etravirine (Compound)
Rilpivirine (Compound) binds CYP3A4 (Gene)
Rilpivirine (Compound) is included by Non-Nucleoside Reverse Transcriptase Inhibitors (Pharmacologic Class)
Rilpivirine (Compound) causes Blood creatinine increased (Side Effect)
Rilpivirine may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Rilpivirine may cause a moderate interaction that could exacerbate diseases when taken with Zafirlukast
Rilpivirine may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Rilpivirine may lead to a major life threatening interaction when taken with Lumacaftor
Rilpivirine may lead to a major life threatening interaction when taken with Ranitidine
Rilpivirine (Compound) resembles Pazopanib (Compound) and Rilpivirine may cause a moderate interaction that could exacerbate diseases when taken with Pazopanib